Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification.
Arielle ElkriefIgor OdintsovRoger S SmithMorana VojnicTakuo HayashiInna KhodosVladimir MarkovZebing LiuAllan J W LuiJamie L BloomMichael D OffinCharles M RudinElisa De StanchinaGregory J RielyRomel SomwarMarc LadanyiPublished in: JCO precision oncology (2024)
These preclinical in vivo data provide a rationale for further clinical development of this combinatorial targeted therapy approach.